Toxicological Profile of Therapeutic Nanodelivery Systems
Luis M. Bimbo, Leena Peltonen, Jouni Hirvonen and Helder A. Santos
Affiliation: Division of Pharmaceutical Technology, Faculty of Pharmacy, P.O. Box 56 (Viikinkaari 5 E), FI-00014 University of Helsinki, Finland.
Keywords: Accumulation, dendrimers, liposomes, mesoporous, nanoparticles, silicon, silica, toxicity, Nanodelivery Systems, Potent, dendrimers, morphology, RNOS, ROS, immunoassays, oxidative stress, SEM, cytotoxicity.
Several of the newly developed drug molecules show potent biological activity, but exhibit poor pharmacokinetic properties
that may hinder their effective delivery to the intended site of action. In order to improve their pharmacological effect, these molecules
can be associated with drug carriers in order to overcome these inherent difficulties. An ideal drug delivery agent requires therefore biocompatibility,
improved solubility of a loaded drug or peptide, releasing of the payload at the absorption site and, at the same time, leaving
undisturbed cell structure and function, and maintaining the physiological milieu. By taking advantage of the valuable properties of
nanoscale delivery systems, such as increased surface area, improved solubility of hydrophobic drugs, possibility to encapsulate and protect
drugs from degradation and reduced immunogenic potential and toxicological effect, new therapeutic options can be brought forth
and improve the clinical arsenal for numerous diseases. The use of nanodelivery systems can even promote the re-investigation of pharmacokinetically
less favourable, but biologically more active compounds. Although very promising, these systems may also encompass
inherent toxicological issues, mainly due to their size and shape, physical interaction with cellular membranes and organelles, immunological
reactions, long- or short-term tissue accumulation, and degradation products. Pharmaceutical nanodelivery systems, such as
liposomes, polymeric nanoparticles, dendrimers and mesoporous silica and silicon based nanoparticles have shown great potential in preclinical
applications and several of these nanosystems are even undergoing clinical trials. They have been found to combine drug delivery
properties with an acceptable toxicological profile, which has made them prime candidates for several drug delivery approaches. This review
aims to provide and correlate the toxicological studies with the drug delivery properties of the abovementioned nanodelivery systems
in particular concerning uptake and accumulation as well as the critical aspects in each system regarding their optimal performance,
while pointing out to the most relevant references.
Rights & PermissionsPrintExport